Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7784011 | 0.72 | MAOA (0.33) | MAOAMAOBCYP2D6TSHRCYP2C19 | |
| SCHEMBL1441712 | 0.71 | PKM (0.41) | MAOAMAOBCYP2D6TSHRCYP2C19 | |
| SCHEMBL2023897 | 0.70 | MAOA (0.42) | MAOAMAOBSIGMAR1CYP2D6TSHR | |
| SCHEMBL2925890 | 0.70 | PPIB (0.41) | SIGMAR1SMN1; SMN2HTR2ADRD2GAA | |
| SCHEMBL5525165 | 0.70 | MAOA (0.38) | MAOAMAOBNPSR1OXTRABCG2 | |
| SCHEMBL30005029 | 0.69 | SIGMAR1 (0.44) | MAOAMAOBSIGMAR1CYP2D6TSHR | |
| SCHEMBL23811463 | 0.68 | CYP2D6 (0.39) | MAOAMAOBCYP2D6TSHRCYP2C19 | |
| SCHEMBL10382409 | 0.68 | CYP2C19 (0.39) | MAOAMAOBCYP2D6TSHRCYP2C19 | |
| SCHEMBL4854732 | 0.68 | SIGMAR1 (0.43) | MAOAMAOBSIGMAR1CYP2D6TSHR | |
| SCHEMBL888447 | 0.68 | TSHR (0.39) | MAOAMAOBCYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022026823-A1 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20240115557-A1 | INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF | THE BROAD INSTITUTE, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11787795-B2 | Inhibitors of RNA guided nucleases and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210177832-A1 | INHIBITORS OF RNA-GUIDED NUCLEASE TARGET BINDING AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-17 | — | — | US | disclosed |
| US-20190263807-A1 | INHIBITORS OF RNA GUIDED NUCLEASES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) | 2019-05-09 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-10172827-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | disclosed |
| EP-2385829-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2010081115-A1 | PRO-NEUROGENIC COMPOUNDS | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
| US-4734121-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
| US-4668275-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| EP-0107156-B1 | CYCLOHEXANE-1,3-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE CONTROL OF UNDESIRABLE PLANT GROWTH | BASF Aktiengesellschaft (DE) | 1986-12-30 | — | — | EP | disclosed |
| EP-0107156-A1 | Cyclohexane-1,3-dione derivatives, process for their preparation and their use in the control of undesirable plant growth | BASF Aktiengesellschaft (DE) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177832-A1 | INHIBITORS OF RNA-GUIDED NUCLEASE TARGET BINDING AND USES THEREOF | RNASEH1, RNASEL, RNASE1 | MAOA 1866/4885MAOB 1325/4885SIGMAR1 4433/4885 |
| US-10172827-B2 | Pro-neurogenic compounds | DCX, GAP43, BDNF | MAOA 2000/4885MAOB 1329/4885SIGMAR1 1003/4885 |
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | MAOA 3028/4885MAOB 2621/4885SIGMAR1 3376/4885 |
| US-20190263807-A1 | INHIBITORS OF RNA GUIDED NUCLEASES AND USES THEREOF | RNASE1, RNASEH1, RNASEL | MAOA 1932/4885MAOB 1452/4885SIGMAR1 4220/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MAOA 1758/4885MAOB 1083/4885SIGMAR1 2231/4885 |
| US-20240115557-A1 | INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF | ZFR, ENDOD1, FEN1 | MAOA 4127/4885MAOB 3941/4885SIGMAR1 4272/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | MAOA 1736/4885MAOB 1109/4885SIGMAR1 2283/4885 |
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | KRAS, NRAS, HRAS | MAOA 4754/4885MAOB 4703/4885SIGMAR1 4020/4885 |
| US-11787795-B2 | Inhibitors of RNA guided nucleases and uses thereof | RNASE1, RNASEH1, RNASEL | MAOA 1932/4885MAOB 1452/4885SIGMAR1 4220/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | MAOA 1996/4885MAOB 1849/4885SIGMAR1 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.